Evaluation of efficacy and safety of fixed dose combination of ceftazidime-tobramycin in comparison with ceftazidime in lower respiratory tract infections

Current Clinical Pharmacology

Volumn 4, Issue 1, 2009, Pages 62-66

  Chaudhary, Manu ^a   Shrivastava, Sanjay Mohan ^a   Sehgal, Rajesh ^a  

^a Venus Remedies Limited   (India)

Author keywords

Ceftazidime; LRTI; P. aeruginosa; Tobramycin

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; CEFTAZIDIME PLUS TOBRAMYCIN; TOBRAMYCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ADULT; BACTERIUM ISOLATE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; KIDNEY FUNCTION TEST; KLEBSIELLA PNEUMONIAE; LIVER FUNCTION TEST; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MONOTHERAPY; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; THORAX RADIOGRAPHY; TREATMENT OUTCOME; AGED; ARTICLE; BACTERIAL INFECTION; COMPARATIVE STUDY; DRUG COMBINATION; INDIA; MIDDLE AGED; MULTICENTER STUDY; RESPIRATORY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CEFTAZIDIME; DRUG COMBINATIONS; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; RESPIRATORY TRACT INFECTIONS; TOBRAMYCIN;

EID: 65549127703     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488409787236119     Document Type: Review

References (15)

1. Macfarlane J, Holmes W, Gard P, et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax 2001;56(2):109-14.
2. Macfarlane J. Community-acquired pneumonia. Br J Dis Chest 1987; 81(2):116-27.
3. Ortiz-Ruiz G, Vetter N, Isaacs R, et al. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies. J Antimicrob Chemother 2004; 53: 59-6.
4. Rains CP, Bryson HM, Peters DH. Ceftazidime, An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1995; 49(4): 577-617.
5. den Hollander JG, Horrevorts AM, van Goor ML, Verbrugh HA, Mouton JW. Synergism between Tobramycin and Ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1997; 41(1): 95-100.
6. Guthrie R. Community-acquired lower respiratory tract infections: etiology and treatment. Chest 2001; 120(6): 2021-34.
7. Rajan S, Saiman L. Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect 2002; 17: 47-56.
8. Master V, Roberts GW, Coulthard KP, et al. Efficacy of once daily Tobramycin therapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study. Pediatr Pulmonol 2001; 31: 367-376.
9. Cade JF, Presneill J, Sinickas V, Hellyar A. The optimal dosage of Ceftazidime for severe lower respiratory tract infections. J Antimicrob Chemother 1993; 32: 61-622.
10. Joshi M, Bernstein J, Solomkin J, Wester BA, Kuye O. Piperacillin/ tazobactam plus Tobramycin versus Ceftazidime plus Tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. J Antimicrob Chemother 1999; 43(3): 389-97.
11. McCabe R, Chirurgi V, Farkas SA, Haddow A, Heinz G, Greene S. A new therapeutic option for the treatment of pneumonia. Am J Med 1996; 100(6A): 60S-67S.
12. Zelenitsky SA, Iacovides H, Harding GK, Ariano RE. Effect of antibiotic sequence on combination regimens against Pseudomonas aeruginosa in a multiple-dose, in vitro infection model. Diagn Microbiol Infect Dis 2004; 49(1): 67-70.
13. Jacobs RF, Vats TS, Pappa KA, Chaudhary S, Kletzel M, Becton DL. Ceftazidime versus Ceftazidime plus Tobramycin in febrile neutropenic children. Infection 1993; 21(4): 223-8.
14. Nisly SA, Ray SM, Moye RA. Tobramycin-Induced Hepatotoxicity. Ann Pharmacother 2007; 41(12): 2061-5.
15. Blumer JL, Saiman L, Konstan MW, Melnick D. The efficacy and safety of meropenem and Tobramycin vs Ceftazidime and Tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005;128(4): 2336-46.